Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of “Hold” by Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been assigned an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.30.

A number of equities analysts recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Friday, January 10th. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wasatch Advisors LP raised its holdings in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after buying an additional 6,483,070 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 2,087,635 shares during the last quarter. State Street Corp raised its holdings in shares of Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Esperion Therapeutics by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after buying an additional 19,588 shares during the last quarter. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Trading Up 2.3 %

Shares of ESPR stock opened at $2.26 on Friday. The firm has a fifty day moving average price of $2.47 and a 200 day moving average price of $2.18. The company has a market cap of $445.30 million, a P/E ratio of -3.53, a PEG ratio of 0.17 and a beta of 1.03. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.